The ICH Q11 Guideline on Development and Manufacture of Drug Substances ( Chemical Entities and Biotechnological/Biological Entities). Step 3. Transmission to CHMP. May Adoption by CHMP for release for ICH guideline Q11 on development and manufacture of drug substances . endorsed by the ICH Assembly at Step 4 of the ICH process, August Do the ICH Q11 general principles for selection of starting materials apply to the.
|Published (Last):||26 January 2006|
|PDF File Size:||11.96 Mb|
|ePub File Size:||20.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
Changes in earlier synthesis steps upstream must be made in accordance with the quality assurance system of the applicant. Residual risks in regards to the drug substance quality are to be assessed. When related substances are at a level that exceeds those limits, an impact on the impurity profile is to be expected. ICH Q11, section 9 describes basic scientific and risk-based concepts for the evaluation of post-approval changes to the starting material.
ICH Q11 reaches Step 4 of the ICH Process : ICH
If a persisting impurity appears at some point during a synthetic route, dtep may be acceptable to control this impurity through the specification of the starting material, even if the impurity profile of the active substance is changed. These concepts should logically be applied to steps upstream of the starting material as well.
Assessors at regulatory agencies of the EU member states have stfp evaluate whether the data provided sufficiently justify the selection. In that case, stel dossier has to describe a control strategy and justify the choice of starting material. Cookies help us in providing our services. The same goes for intermediates that do not count as “commercially available” according to ICH Q The criteria for this are outlined in the ICH Q11 guideline – however, not in a sufficiently precise manner.
ICH Q11 Q&A reaches Step 4
The selection of a starting material for the synthesis of an active substance and its justification is often one of the most crucial steps in the approval process. Stwp term “custom synthesised” is not defined in ICH Q11; it is generally understood to be a substance which has been synthesised specifically for pharmaceutical manufacture and in consideration of a customers’ requirements. Yes, the terms are synonymous.
Together with the recently published updated EMA reflection paper on API starting materialsthe applicants as well as the assessors are now provided with sufficiently detailed documents, which lay the foundations for a more harmonised interpretation of ICH Q However, the regulations in ICH Q7 relate to the GMP compliant manufacture of active substances, not the procedure of icy and justifying starting materials.
In order to establish a common understanding in regards to the information on starting materials in module 3 section 3. In cases such as this, a detailed description of all synthesis steps in which these impurities are formed may be forgone in the dossier section 3.
This is covered by ICH Q It remains to be seen whether this will speed up approval processes.
This resulted in questions and additional demands by the agencies, thereby delaying the approval processes. The distinction between these two terms plays an important role in ICH Q11 insofar as that an applicant does not have to justify the use of a “commercially available” substance as a starting material in the dossier – on the contrary to “custom synthesised” compounds; those are subject to the regulations of ICH Q